Guotai Junan International: Raises Sanescare Pharmaceutical (01530.HK) target price to 33 Hong Kong dollars, maintains "buy" rating.

Wisdom Financial APP learned that CICC released a research report stating that based on higher cooperation revenue forecasts, the revenue forecasts for Sanesc Pharmaceuticals (01530.HK) for 2025-2027 have been raised by 2-6%; At the same time, considering the contribution of high-priced innovative drugs and high-profit margin cooperation revenue to total revenue gradually increasing, the profit margin forecast has been raised, and the net profit forecast has also been raised by 6-9%. The target price has been raised to 33 Hong Kong dollars, corresponding to 25.8 times and 23.9 times the price-earnings ratio for 2025/2026, maintaining a "buy" rating.